Asia-Pacific Biosensors Market

Asia-Pacific Biosensors Market Size(2024 to 2029)

The biosensors market in Asia-Pacific is expected to grow at a CAGR of 9.75% from 2024 to 2029 and be valued at USD 10.47 billion by 2029, up from USD 6.57 billion in 2024.

Biosensors are devices that are utilized to detect the presence or concentration of a biological analyte, like an anatomical structure, a microorganism, or a biomolecule. These biosensors consist of three major parts, which include a component for recognizing the analyte and producing a signal, a transducer of the message, and a reader device. And the reader device connects through the associated electronics or signal processors which are primarily responsible for the display of the results in a user-friendly way.

The growth of the biosensors market in the Asia-Pacific region is attributed to the rising usage of biosensors to monitor glucose levels in individuals with diabetes and the increasing demand for disposable, cost-efficient & user-friendly devices in the market. The significant technological advancements in the field of biosensor technology and the high demand for biosensors in monitoring & diagnostic devices of the market are the major drivers for the growth of the Asia-Pacific biosensor market. Also, the growing awareness regarding the large population base, clinical outcomes, rise in the geriatric population, growth in diabetic population and technological advancement in medical devices and equipment are the other factors that are boosting the biosensors market in this region. The increasing use of biosensors to monitor glucose levels in individuals who are with diabetes, along with rising demand for disposable, cost-efficient & user-friendly devices, are anticipating the growth of the target market in the Asia-Pacific region during the outlook period.

This research report on the Asia-Pacific biosensors market has been segmented and sub-segmented based on the following categories.

By Product Type

• Non-wearable
• Wearable

By Technology

• Electrochemical
  • Amperometric Sensors
  • Potentiometric Sensors
  • Conductometric Sensors
• Piezoelectric
• Thermal & Optical

Among these all the segments, the electrochemical section held for the largest share of the worldwide market in 2023 and is expected to continue registering the domination of the global market over the forecast period. The optical segment is the segment that has been multiplying, at the fastest CAGR of 12.9 % during the forecast period.

By End-User

• Point of Care Testing
  • Glucose Monitoring
  • Cardiac Markers
  • Infectious Diseases
  • Coagulation Monitoring
  • Pregnancy & Fertility Testing
  • Blood Gas & Electrolytes
  • Tumour Or Cancer Markers
  • Urinalysis Testing
  • Cholesterol Tests
  • Others
• Home healthcare Diagnostics
• Research Laboratories
• Food Industry
• Others

By Application

• Medical Applications
  • Cholesterol Testing
  • Pregnancy Testing
  • Blood Gas Analyzer
  • Infectious Diseases
• Agriculture
• Environment
• Food Toxicity
• Others

Of these, the medical applications accounted for a prominent share in the regional market.

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

In all of these regions, Japan accounted for the largest share of Asia Pacific biosensor market revenue and is estimated to get valued around USD 2928.16 million over the forecast period. China is the fastest-growing region which is likely to record a CAGR of 13.0% during the forecasted period.

KEY PLAYERS IN THE ASIA-PACIFIC BIOSENSORS MARKET

Companies playing a key role in the Asia-Pacific biosensors market include Danaher Corporation, ABBOTT Laboratories, Siemens AG, AGAMATRIX, INC., Bayer AG, Johnson and Johnson, LifeSensors, Inc., Medtronic Plc., Bio-Rad Laboratories, Inc., and Analog Devices, Inc.

RECENT HAPPENINGS IN THE ASIA-PACIFIC MARKET

• LineaRx, Inc., a STONY BROOK N.Y majority-owned subsidiary focused on next-generation biotherapeutics and cancer diagnostics, has announced that they have signed a licensing agreement with LifeSensors, Inc., a significant player in biosensor market, to incorporate LifeSensors’ high expression SUMO-fusion technologies into the Company’s linear DNA amplicons designed and produced for therapeutic applications.
• Johnson & Johnson has announced that its Janssen Pharmaceutical Companies have collaborated with the Beth Israel Deaconess Medical Center to support the development of a preventive vaccine candidate for COVID-19.